IXICO is a leadering provider at the forefront of advancing Alzheimer's disease (AD) imaging biomarkers, having focused on AD clinical research since 2007. We have conducted over 40 Alzheimer's disease studies, bringing together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.
In both EPAD and AMYPAD international consortia projects, IXICO data analysis algorithms have quantitatively analysed brain scans, to maximize the information extracted and increase chances of detecting therapy-induced changes in clinical trials. IXICO's artificial intelligence data analytics will be used to combine imaging with other data captured from patients, to predict the rate of disease progression in individual patients and identify those people who could benefit from enrolment in clinical trials aimed at preventing Alzheimer’s disease.